* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20...
SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named t...
* The only company from pharmaceutical industry selected for inclusion in the Index * Also incl...
SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integratio...
SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Resear...
WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...
* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span ...
* Committed to net-zero across the value chain by 2050 * Aligned with 1.5°C mitigation pathways,...
* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operation...
* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ pla...
* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quali...
* Earns CDP's highest rating for supply chain engagement on climate * Adds to other CDP recognit...
* Innovative modular design will accelerate construction and manufacturing timelines, enabling ra...
* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regi...
* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to en...